Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation

Journal of Immunology

Volumn 174, Issue 5, 2005, Pages 3087-3097

  Schaft, Niels ^a   Dörrie, Jan ^a   Thumann, Peter ^a   Beck, Verena E ^a   Müller, Ina ^a   Schultz, Erwin S ^a   Kämpgen, Eckhart ^a   Dieckmann, Detlef ^a   Schuler, Gerold ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; EPITOPE; MELAN A; MELANOMA ANTIGEN 3; RNA; SURVIVIN;

ANTIGEN EXPRESSION; ARTICLE; CELL MATURATION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

EID: 14044261257     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.5.3087     Document Type: Article

References (59)

1. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138.
2. Ridgway, D. 2003. The first 1000 dendritic cell vaccinees. Cancer Invest. 21:873.
3. Coulie, P. G., and P. Van Der Bruggen. 2003. T-cell responses of vaccinated cancer patients. Curr. Opin. Immunol 15:131.
4. Cerundolo, V., I. F. Hermans, and M. Salio. 2004. Dendritic cells: a journey from laboratory to clinic. Nat. Immunol. 5:7.
5. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685.
6. + regulatory T cells in vivo in humans. Blood 100:174.
7. Roncarolo, M. G., M. K. Levings, and C. Traversari. 2001. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193:F5.
8. Slingluff, C. L., Jr., G. R. Petroni, G. V. Yamshchikov, D. L. Barnd, S. Eastham, H. Galavotti, J. W. Patterson, D. H. Deacon, S. Hibbitts, D. Teates, et al. 2003. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol 21:4016.
9. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10:475.
10. Romani, N., S. Gruner, D. Brang, E. Kämpgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med 180:83.
11. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109.
12. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kämpgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J. Immunol. Methods 196:137.
13. Jonuleit, H., U. Kuhn, G. Muller, K. Steinbrink, L. Paragnik, E. Schmitt, J. Knop, and A. H. Enk. 1997. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol 27:3135.
14. 2. Blood 103:1595.
15. Berger, T. G., B. Feuerstein, E. Strasser, U. Hirsch, D. Schreiner, G. Schuler, and B. Schuler-Thurner. 2002. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J. Immunol. Methods 268:131.
16. Feuerstein, B., T. G. Berger, C. Maczek, C. Roder, D. Schreiner, U. Hirsch, I. Haendle, W. Leisgang, A. Glaser, O. Kuss, et al. 2000. A method for the production of cryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use. J. Immunol. Methods 245:15.
17. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch, et al. 1999. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
18. Godelaine, D., J. Carrasco, S. Lucas, V. Karanikas, B. Schuler-Thurner, P. G. Coulie, G. Schuler, T. Boon, and A. Van Pel. 2003. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J. Immunol. 171:4893.
19. Schuler-Thurner, B., E. S. Schultz, T. G. Berger, G. Weinlich, S. Ebner, P. Woerl, A. Bender, B. Feuerstein, P. O. Fritsch, N. Romani, and G. Schuler. 2002. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:1279.
20. Schultz, E. S., B. Schuler-Thurner, V. Stroobant, L. Jenne, T. G. Berger, K. Thielemanns, P. Van Der Bruggen, and G. Schuler. 2004. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J. Immunol. 172:1304.
21. Banchereau, J., B. Schuler-Thurner, A. K. Palucka, and G. Schuler. 2001. Dendritic cells as vectors for therapy. Cell 106:271.
22. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
23. Heiser, A., D. Coleman, J. Dannull, D. Yancey, M. A. Maurice, C. D. Lallas, P. Dahm, D. Niedzwiecki, E. Gilboa, and J. Vieweg. 2002. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:409.
24. Strobel, I., S. Berchtold, A. Gotze, U. Schulze, G. Schuler, and A. Steinkasserer. 2000. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther. 7:2028.
25. Van Tendeloo, V. F., P. Ponsaerts, F. Lardon, G. Nijs, M. Lenjou, C. Van Broeckhoven, D. R. Van Bockstaele, and Z. N. Berneman. 2001. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98:49.
26. + hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J. Immunol. Methods 285:171.
27. Saeboe-Larssen, S., E. Fossberg, and G. Gaudernack. 2002. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J. Immunol. Methods 259:191.
28. Kalady, M. F., M. W. Onaitis, K. M. Padilla, S. Emani, D. S. Tyler, and S. K. Pruitt. 2002. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J. Surg. Res. 105:17.
29. Tuyaerts, S., A. Michiels, J. Corthals, A. Bonehill, C. Heirman, C. De Greef, S. M. Noppe, and K. Thielemans. 2003. Induction of influenza matrix protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther. 10:696.
30. Kocher, T., E. Schultz-Thater, F. Gudat, C. Schaefer, G. Casorati, A. Juretic, T. Willimann, F. Harder, M. Heberer, and G. C. Spagnoli. 1995. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 55:2236.
31. Ambrosini, G., C. Adida, and D. C. Altieri. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3:917.
32. Heiser, A., P. Dahm, D. R. Yancey, M. A. Maurice, D. Boczkowski, S. K. Nair, E. Gilboa, and J. Vieweg. 2000. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol 164:5508.
33. Schultz, E. S., Y. Zhang, R. Knowles, J. Tine, C. Traversari T. Boon, and P. Van Der Bruggen. 2001. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 57:103.
34. Morel, S., F. Levy, O. Burlet-Schiltz, F. Brasseur, M. Probst-Kepper, A. L. Peitrequin, B. Monsarrat, R. Van Velthoven, J. C. Cerottini, T. Boon, et al. 2000. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 12:107.
35. 2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100:1354.
36. Pittet, M. J., A. Zippelius, D. Valmori, D. E. Speiser, J. C. Cerottini, and P. Romero. 2002. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 23:325.
37. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708.
38. L. Cancer Immunol. Immunother. 51:139.
39. Leverkus, M., H. Walczak, A. McLellan, H. W. Fries, G. Terbeck, E. B. Brocker, and E. Kämpgen. 2000. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood 96:2628.
40. Li, X., X. Zhao, Y. Fang, X. Jiang, T. Duong, C. Fan, C. C. Huang, and S. R. Kain. 1998. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 273:34970.
41. Zhao, J., T. Tenev, L. M. Martins, J. Downward, and N. R. Lemoine. 2000. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 113(Pt. 23):4363.
42. Wang, R. F., and H. Y. Wang. 2002. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol. 20:149.
43. Schreiber, H., T. H. Wu, J. Nachman, and W. M. Kast. 2002. Immunodominance and tumor escape. Semin. Cancer Biol. 12:25.
44. Jager, E., M. Ringhoffer, M. Altmannsberger, M. Arand, J. Karbach, D. Jager, F. Oesch, and A. Knuth. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer 71:142.
45. Seliger, B., U. Ritz, R. Abele, M. Bock, R. Tampe, G. Sutter, I. Drexler, C. Huber, and S. Ferrone. 2001. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 61:8647.
46. Palmowski, M. J., E. M. Choi, I. F. Hermans, S. C. Gilbert, J. L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, et al. 2002. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168:4391.
47. Zehn, D., C. J. Cohen, Y. Reiter, and P. Walden. 2004. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Eur. J. Immunol. 34:1551.
48. Cella, M., A. Engering, V. Pinet, J. Pieters, and A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.
49. Cohen, C. J., G. Denkberg, A. Lev, M. Epel, and Y. Reiter. 2003. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 16:324.
50. Lelouard, H., E. Gatti, F. Cappello, O. Gresser, V. Camosseto, and P. Pierre. 2002. Transient aggregation of ubiquitinated proteins during dendritic cell maturation. Nature 417:177.
51. Ardavin, C., S. Amigorena, and E. Reis e Sousa. 2004. Dendritic cells: immunobiology and cancer immunotherapy. Immunity 20:17.
52. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
53. Abdel-Wahab, Z., M. F. Kalady, S. Emani, M. W. Onaitis, O. I. Abdel-Wahab, R. Cisco, L. Wheless, T. Y. Cheng, D. S. Tyler, and S. K. Pruitt. 2003. Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution. Cell. Immunol. 224:86.
54. Macagno, A., L. Kuehn, R. de Giuli, and M. Groettrup. 2001. Pronounced upregulation of the PA28α/β proteasome regulator but little increase in the steady-state content of immunoproteasome during dendritic cell maturation. Eur. J. Immunol. 31:3271.
55. Choi, E. M., J. L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I. F. Hermans, J. D. Silk, F. Mirza, M. J. Palmowski, et al. 2003. High avidity antigen-specific CTL identified by CD8-independent tetramer staining. J. Immunol. 171:5116.
56. Liao, X., Y. Li, C. Bonini, S. Nair, E. Gilboa, P. D. Greenberg, and C. Yee. 2004. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol. Ther. 9:757.
57. Heil, F., H. Hemmi, H. Hochrein, F. Ampenberger, C. Kirschning, S. Akira, G. Lipford, H. Wagner, and S. Bauer. 2004. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303:1526.
58. + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. J. Immunol. 171:2251.
59. Bonehill, A., C. Heirman, S. Tuyaerts, A. Michiels, K. Breckpot, F. Brasseur, Y. Zhang, P. Van Der Bruggen, and K. Thielemans. 2004. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol. 172:6649.